Attovia Therapeutics (ATTO): venBio fund converts preferred in IPO, buys $17 shares
Rhea-AI Filing Summary
venBio Global Strategic Fund IV, L.P., a 10% owner of Attovia Therapeutics, Inc., reported multiple equity transactions tied to Attovia’s initial public offering. On August 6, 2026, the fund converted 21,477,273 Series A, 7,636,362 Series B, and 6,179,219 Series C Preferred Stock shares into Common Stock as part of an automatic conversion at IPO, as adjusted for a 1-for-9.29 reverse stock split effective July 29, 2026. The filing also reports an additional open-market purchase of 382,352 Common Stock shares at $17.00 per share. These securities are held directly by venBio Global Strategic Fund IV, L.P.; its general partner entities and members disclaim beneficial ownership beyond their pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Net Buyer: 4,181,367 shares
Net Buy
7 txns
Insider
venBio Global Strategic Fund IV, L.P.
Role
10% Owner
Bought
382,352 shs ($6.50M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Preferred Stock F1, F2 | 21,477,273 | $0.00 | $0.00 |
| Conversion | Series B Preferred Stock F1, F2 | 7,636,362 | $0.00 | $0.00 |
| Conversion | Series C Preferred Stock F1, F2 | 6,179,219 | $0.00 | $0.00 |
| Conversion | Common Stock F1, F2 | 2,311,870 | -- | -- |
| Conversion | Common Stock F1, F2 | 821,998 | -- | -- |
| Conversion | Common Stock F1, F2 | 665,147 | -- | -- |
| Purchase | Common Stock F2 | 382,352 | $17.00 | $6.50M |
Holdings After Transaction:
Series A Preferred Stock — 0 shares (Direct);
Series B Preferred Stock — 0 shares (Direct);
Series C Preferred Stock — 0 shares (Direct);
Common Stock — 4,181,367 shares (Direct)
Footnotes (2)
- F1. In connection with the completion of the Issuer's initial public offering of its common stock ("Common Stock"), each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of Common Stock on a one-for-one basis, as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock effected on July 29, 2026, without payment of further consideration.
- F2. These securities are held directly by venBio Global Strategic Fund IV, L.P. ("Fund IV"). venBio Global Strategic GP IV, LLC ("General Partner IV") is the sole general partner of Fund IV. Richard Gaster, Corey Goodman, and Aaron Royston are the members of General Partner IV, and, in reliance on the "rule of three," each disclaims beneficial ownership over the securities held directly by Fund IV.
Key Figures
Series A Preferred Converted: 21,477,273 shares
Series B Preferred Converted: 7,636,362 shares
Series C Preferred Converted: 6,179,219 shares
+4 more
7 metrics
Series A Preferred Converted
21,477,273 shares
Shares of Series A Preferred Stock converted into Common Stock on August 6, 2026
Series B Preferred Converted
7,636,362 shares
Shares of Series B Preferred Stock converted into Common Stock on August 6, 2026
Series C Preferred Converted
6,179,219 shares
Shares of Series C Preferred Stock converted into Common Stock on August 6, 2026
Total Preferred Shares Converted
35,292,854 shares
Aggregate preferred shares converted, as shown in transactionSummary exerciseShares
Common Stock Purchased
382,352 shares
Non-derivative purchase of Common Stock on August 6, 2026
Purchase Price
$17.00 per share
Price for the 382,352 Common Stock shares purchased
Reverse Stock Split Ratio
1-for-9.29
Reverse split of Common Stock effective July 29, 2026
Key Terms
reverse stock split, initial public offering, Preferred Stock, beneficial ownership, +1 more
5 terms
reverse stock split financial
"as adjusted to reflect the 1-for-9.29 reverse stock split of the Common Stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
initial public offering financial
"In connection with the completion of the Issuer's initial public offering of its common stock"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
Preferred Stock financial
"each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock"
Preferred stock is a type of ownership in a company that typically offers investors higher and more consistent dividend payments than common stock. Unlike regular shares, preferred stock usually doesn’t come with voting rights but provides a priority claim on the company’s assets and profits, making it a more stable and predictable investment option. This makes preferred stock attractive to those seeking steady income with lower risk.
beneficial ownership financial
"each disclaims beneficial ownership over the securities held directly by Fund IV"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
rule of three financial
"and, in reliance on the "rule of three," each disclaims beneficial ownership"
FAQ
What insider transactions did venBio report in ATTO on August 6, 2026?
venBio Global Strategic Fund IV reported conversions of Series A, B and C Preferred Stock into Common Stock and an additional purchase of 382,352 Common Stock shares at $17.00 per share, all dated August 6, 2026.
What common stock did venBio acquire in Attovia (ATTO) beyond the conversions?
In addition to conversion-related Common Stock, venBio Global Strategic Fund IV acquired 382,352 shares of Common Stock in a purchase transaction at $17.00 per share, reported as a non-derivative transaction dated August 6, 2026.
How is the Attovia (ATTO) reverse stock split reflected in venBio’s Form 4?
The filing states that each preferred share automatically converted into Common Stock on a one-for-one basis, as adjusted for a 1-for-9.29 reverse stock split of Attovia’s Common Stock that was effected on July 29, 2026.
Who legally holds the Attovia (ATTO) securities reported in this Form 4?
The securities are held directly by venBio Global Strategic Fund IV, L.P.. venBio Global Strategic GP IV, LLC is its sole general partner, and its members rely on the “rule of three” to disclaim beneficial ownership beyond any pecuniary interest.
Does this Attovia (ATTO) Form 4 involve a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as relying on a trading plan. The transactions, including the preferred stock conversions and the $17.00 per-share purchase, are reported without reference to a pre-arranged 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
